Veracyte Reports 25 Percent Q3 Revenue Growth, Raises Full-Year Guidance
The firm said that its Decipher and Afirma tests each benefited from expanded coverage and largely drove growth this quarter.
Veracyte Q2 Revenues up 32 Percent, Beat Analyst Expectations
The firm said the growth was due primarily to its portfolio of urology tests, which it brought on through its acquisition of Decipher Biosciences.
Akoya Biosciences, Acrivon Therapeutics Partner to Develop CDx
The companies will codevelop, validate, and commercialize a companion diagnostic for Acrivon's targeted DNA damage response inhibitor therapy, ACR-368.
OraSure Technologies Acquires CoreBiome, Novosanis
The company also reaffirmed its guidance for the fourth quarter, and continues to expect revenues of $46.5 million to $48.0 million and EPS of $.09 to $.11.
FDA Approves Expanded Use of Agilent Assay as Keytruda CDx for Urothelial Cancer
Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify urothelial carcinoma patients who may benefit from the anti-PD1 immunotherapy.